The impact of elexacaftor/tezacaftor/ivacaftor on body composition in a small cohort of youth with cystic fibrosis

Andrea Granados, Christine L. Chan, Amir Moheet, Timothy Vigers, Ana María Arbeláez, Katie Larson Ode

Research output: Contribution to journalLetterpeer-review

2 Scopus citations

Abstract

Background: The effects of elexacaftor-tezacaftor-ivacaftor (ETI) on body composition in people with CF (pwCF) are unknown. Methods: Dual-energy X-ray absorptiometry fat-free mass and fat mass adjusted for height (FMI) as well as oral glucose tolerance test derived measures of insulin secretion and sensitivity were compared before and after ETI initiation in eight pwCF. Results: Patients median age: 22 years interquartile range (IQR: 16–28), 87.5% male, median time on ETI:11 months. Weight z-score increased from −0.52 to 0.18 (p = 0.014); FMI increased from 4.12 to 6.29 (p = 0.014). Insulin secretion (C pep iAUC/Gluc iAUC) increased from 8.71 to 14.21 (p = 0.021), insulin resistance (HOMA2 IR) increased from 0.73 to 1.25 (p = 0.014) and insulin sensitivity decreased (Matsuda) 8.88 to 5.58 (p = 0.036). Conclusions: ETI resulted in increased weight and fat mass. BMI and muscle mass did not change. Both insulin secretion and insulin resistance increased. Longer-term metabolic consequences of ETI need further investigation.

Original languageEnglish (US)
Pages (from-to)1805-1811
Number of pages7
JournalPediatric pulmonology
Volume58
Issue number6
DOIs
StatePublished - Jun 2023

Bibliographical note

Funding Information:
The authors thank the study participants and their families, the coordinators at all four sites, and Julie Coffey ARNP, leader of the coordinating center for the larger study. This work was supported by Cystic Fibrosis Foundation Grant LARSON18A0 (KLO).

Publisher Copyright:
© 2023 Wiley Periodicals LLC.

Keywords

  • body composition
  • elexacaftor/tezacaftor/ivacaftor
  • fat mass
  • free fat mass
  • insulin secretion
  • muscle mass
  • nutrition

PubMed: MeSH publication types

  • Letter
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'The impact of elexacaftor/tezacaftor/ivacaftor on body composition in a small cohort of youth with cystic fibrosis'. Together they form a unique fingerprint.

Cite this